Evidence map›Paper›PMID 11389700›Full record

ArticleThe Biochemical journal2001

Inhibition of peroxisome-proliferator-activated receptor (PPAR)alpha by MK886.

J P Kehrer, S S Biswal, E La, P Thuillier, K Datta, S M Fischer, J P Vanden Heuvel

Open access · bronzeAbstract read
In one paragraph

Article in The Biochemical journal, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 150 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Vitamin D improves hepatic steatosis in NAFLDFrontiers in endocrinology · 2023
    Article
  7. Review
  8. Review
  9. Toxins · 2020
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. FADD is a key regulator of lipid metabolism.EMBO molecular medicine · 2016
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

J P KehrerDivision of Pharmacology and Toxicology, College of Pharmacy, The University of Texas, Austin, TX 78712, USA. kehrerjim@mail.utexas.edu
S S Biswal
E La
P Thuillier
K Datta
S M Fischer
J P Vanden Heuvel
The University of Texas at Austin · US

Funding

Pilot Project ProgramP30ES007784 · NIEHS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI STROM, SARA S. · 1996 to 2011
$16.4M
EICOSANOID SYNTHESIS AND FUNCTION IN CORONARY VESSELSR01HL051055 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI CAMPBELL, WILLIAM BRYSON · 1994 to 2010
$3.3M
APOPTOSIS,5 LIPOXYGENASE ACTIVATING PROTEIN AND BCL XR01CA083701 · NCI · UNIVERSITY OF TEXAS AUSTIN · PI KEHRER, JAMES P · 2000 to 2004
$1.3M
Peroxisome proliferator-dependent gene regulationR01DK049009 · NIDDK · PENNSYLVANIA STATE UNIVERSITY-UNIV PARK · PI VANDEN HEUVEL, JOHN P · 2001 to 2004
$824k
ROLE OF ARACHIDONATE METABOLITES IN TUMOR PROMOTIONR01CA034443 · NCI · UNIVERSITY OF TEXAS MD ANDERSON CAN CTR · PI FISCHER, SUSAN M · 1985 to 2000
$292k
MECHANISM OF ANTIPROLIFERATIVE ACTIVITY OF ACROLEINF32ES005896 · NIEHS · UNIVERSITY OF TEXAS AUSTIN · PI BISWAL, SHYAM · 1999 to 2001
$9k
PEROXISOME PROLIFERATOR-DEPENDENT GENE REGULATIONR29DK049009 · NIDDK · PURDUE UNIVERSITY WEST LAFAYETTE · PI VANDEN HEUVEL, JOHN P · 1995 to 1999
–
NCI NIH HHS CA34443NCI NIH HHS CA83701NHLBI NIH HHS HL51055NIDDK NIH HHS DK49009NIEHS NIH HHS ES07784NIEHS NIH HHS F32 ES05896
6 · The paper itself

Abstract

Although MK886 was originally identified as an inhibitor of 5-lipoxygenase activating protein (FLAP), recent data demonstrate that this activity does not underlie its ability to induce apoptosis [Datta, Biswal and Kehrer (1999) Biochem. J. 340, 371--375]. Since FLAP is a fatty-acid binding protein, it is conceivable that MK886 may affect other such proteins. A family of nuclear receptors that are activated by fatty acids and their metabolites, the peroxisome-proliferator-activated receptors (PPARs), have been implicated in apoptosis and may represent a target for MK886. The ability of MK886 to inhibit PPAR-alpha, -beta and -gamma activity was assessed using reporter assay systems (peroxisome-proliferator response element--luciferase). Using a transient transfection system in monkey kidney fibroblast CV-1 cells, mouse keratinocyte 308 cells and human lung adenocarcinoma A549 cells, 10--20 microM MK886 inhibited Wy14,643 activation of PPAR alpha by approximately 80%. Similar inhibition of PPAR alpha by MK886 was observed with a stable transfection reporter system in CV-1 cells. Only minimal inhibitory effects were seen on PPAR beta and PPAR gamma. MK886 inhibited PPAR alpha by a non-competitive mechanism as shown by its effects on the binding of arachidonic acid to PPAR alpha protein, and a dose-response study using a transient transfection reporter assay in COS-1 cells. An assay assessing PPAR ligand-receptor interactions showed that MK886 prevents the conformational change necessary for active-complex formation. The expression of keratin-1, a protein encoded by a PPAR alpha-responsive gene, was reduced by MK886 in a culture of mouse primary keratinocytes, suggesting that PPAR inhibition has functional consequences in normal cells. Although Jurkat cells express all PPAR isoforms, various PPAR alpha and PPAR gamma agonists were unable to prevent MK886-induced apoptosis. This is consistent with MK886 functioning as a non-competitive inhibitor of PPAR alpha, but may also indicate that PPAR alpha is not directly involved in MK886-induced apoptosis. Although numerous PPAR activators have been identified, the results show that MK886 can inhibit PPAR alpha, making it the first compound identified to have such an effect.

Indexed as

AnimalsApoptosisChlorobenzenesCOS CellsGene Expression RegulationHumansIndolesPeroxisome ProliferatorsReceptors, Cytoplasmic and NuclearTranscription FactorsTumor Cells, CulturedChlorobenzenesIndolesMK-886Peroxisome ProliferatorsReceptors, Cytoplasmic and NuclearTranscription Factors

Identifiers

PMID11389700
PMCPMC1221919
OpenAlexW83606850

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.